Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel(R)), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group,
“Marinated shredded chicken with jelly fish served cold” @ Yok Chinese Restaurant
—
Yok Chinese Restaurant of the Emerald Hotel would like to invite you t...